# Bristol-Myers Squibb Company (BMY) — Q4-2019 Earnings Results

**Report date:** 2020-02-06 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q4-2019

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Up 2.3%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.22 | N/A | +29.96% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management highlighted the strong EPS results as a positive sign. They emphasized their commitment to advancing their product pipeline.

**Key quotes:**

> Management expressed satisfaction with the EPS performance despite not providing revenue figures.

> The focus remains on long-term growth and pipeline development.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Bristol Myers Squibb's strong EPS performance indicates effective cost management and operational efficiency. The stock rose by 2.3%, reflecting investor confidence in the company's future prospects, despite the lack of revenue data and guidance. The positive surprise in EPS suggests that the company is on the right track, even as it navigates uncertainties in the market.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q4-2019_